Fig. 3

Antiretroviral therapy does not impact on growth changes in IL-10 − / − mice. A SvEv WT and IL-10 − / − mice commenced intervention aged 4 weeks with control (placebo) or cART for 12 weeks ± 1 week with daily nucleoside reverse transcriptase inhibitors (1 mg emtricitabine and 1.5 mg tenofovir disoproxil fumarate) and protease inhibitors (4 mg lopinavir boosted with 1 mg ritonavir) in drinking water. Body weight was continuously measured. Interventions occurred at 12 weeks at which times histology tissue scores, mucosal cytokine production, and viral assessments were performed. B Mouse weight, expressed as a percentage change compared to week 0, was measured every 2 weeks over a total of 12 weeks (mean ± SEM, ****p < 0.0001, **p < 0.01, *p < 0.05)